Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats.

Gastroenterology

Unité de Recherches de Physiopathologie Hépatique (INSERM U-24), Hôpital Beaujon, Clichy, France.

Published: December 1991

The mechanisms of biliary excretion of iron are not well known. The aim of this study was to examine the effect of choleresis induced by several agents on biliary iron excretion in iron-loaded rats. Iron overload was obtained with a diet supplemented by 3% iron carbonyl during a 6-week period. Bile was collected with an external bile fistula. Biliary iron concentration was measured by atomic absorption spectrophotometry, and hepatic iron concentration was measured by a chemical method. Compared with controls, iron overload resulted in a 14-fold increase in hepatic iron concentration but only a 3.9-fold increase in biliary iron output. In iron-loaded rats, taurocholate infusion caused a 1.8-fold significant increase in biliary iron output. Dehydrocholate, given at the same dose, induced a significant but less pronounced (1.3-fold) increase in biliary iron output in spite of a higher bile flow. Taurochenodeoxycholate, tauroursodeoxycholate, and tauro-7-ketolithocholate induced an increase in biliary iron output similar to that observed with taurocholate. The canalicular bile salt-independent choleretic dihydroxydibutyl ether caused a significant but less pronounced increase in biliary iron output (1.4-fold). These results confirm that in iron-loaded rats biliary iron excretion is increased much less than hepatic iron concentration. They show that in iron loaded rats (a) bile salts can increase biliary iron secretion, and (b) this increase is related in part to choleresis and in part to bile salts themselves. This increase may be related to an interaction of iron with bile salt monomers and/or micelles.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0016-5085(91)90407-cDOI Listing

Publication Analysis

Top Keywords

biliary iron
36
increase biliary
28
iron output
20
iron
19
iron-loaded rats
16
iron concentration
16
bile salts
12
salts increase
12
hepatic iron
12
biliary
11

Similar Publications

Iron and Copper Liver Concentrations in Wilson Disease.

J Gastrointestin Liver Dis

December 2024

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Background And Aims: Wilson disease (WD) results in the defective incorporation of copper into ceruloplasmin as well as decreased biliary copper excretion. Secondary iron overload has also been associated with WD; however, the prevalence is currently unknown. This study aims to determine the prevalence of potential secondary iron overload in patients suspected to have WD.

View Article and Find Full Text PDF

Manganese (Mn), a trace element, has been documented to exert an important role in the metabolism of cholesterol. Cholesterol gallstone (CG) pathogenesis is directly linked to biliary cholesterol imbalance which could be due to diabetes complications or mismanagement. NF-κβ pathway, an inflammatory regulator, has been implicated in metabolic disease especially in the context of diabetes and gallstone formation.

View Article and Find Full Text PDF

BACKGROUND Open injury of multiple organs in the chest and abdomen, such as the colon, duodenum, kidney, liver and diaphragm, is relatively rare. The rescue of such a patient is difficult, and the results are often unsatisfactory. It is also a challenge for the hospital and doctors.

View Article and Find Full Text PDF
Article Synopsis
  • - The text discusses challenges in delivering antifibrotic drugs to the liver due to physical barriers and clearance mechanisms, prompting the development of a new delivery strategy aimed at treating liver fibrosis.
  • - This strategy involves a combination of a drug generator called Pro-HAase, which is injected, and an oral iron chelator named deferasirox (DFX), creating a targeted release of antifibrotic agents specifically in the fibrotic liver.
  • - The approach effectively reverses liver fibrosis while minimizing toxicity related to residual iron, showcasing a sophisticated method for overcoming drug delivery barriers in liver treatment, potentially guiding future designs for similar nanomaterial systems.
View Article and Find Full Text PDF

Introduction: Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPARα) agonist activity and selectivity than existing PPARα agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!